The company announced positive Phase III data testing Litfulo in vitiligo, for which AbbVie’s Rinvoq is pending at the US FDA with Incyte’s povorcitinib just behind.
The company announced positive Phase III data testing Litfulo in vitiligo, for which AbbVie’s Rinvoq is pending at the US FDA with Incyte’s povorcitinib just behind.